Neurogene (NGNE) Non-Current Deferred Tax Liability (2013 - 2014)
Neurogene's (NGNE) quarterly Non-Current Deferred Tax Liability came in at $1.8 million in Q4 2014, little changed YoY from $1.8 million in Q4 2013, and little changed on a QoQ basis from $1.8 million in Q1 2014.
Analysis
Neurogene (NGNE) Non-Current Deferred Tax Liability (2013 - 2014) Analysis & Trends
Neurogene (NGNE) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $1.8 million in Q4 2014.
- Quarterly Non-Current Deferred Tax Liability changed 0.02% year-over-year to $1.8 million in Q4 2014, while the trailing twelve-month figure through Dec 2014 was $1.8 million (changed 0.02% YoY) and the FY2014 annual result came in at $1.8 million, changed 0.02% from the prior year.
- Non-Current Deferred Tax Liability held at $1.8 million in Q4 2014, from $1.8 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.8 million in Q4 2013 to a low of $1.8 million in Q4 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Neurogene | 864.53 Mn | 864.53 Mn | - |